Why the study?
Does the use of aldosterone antagonists, ACE inhibitors, and ARBs increase the risk of hyperkalaemia in patients with heart failure?
Does the use of aldosterone antagonists, ACE inhibitors, and ARBs increase the risk of hyperkalaemia in patients with heart failure?
Answers are grounded in this paper and cite their sources.
This review highlights the critical need to monitor for hyperkalaemia in heart failure patients treated with aldosterone antagonists, ACE inhibitors, and ARBs to prevent life-threatening events.
The risk of hyperkalaemia in patients with heart failure has increased in the past few years together with the evolution of pharmacological treatment for these patients. This significant change has been associated with the introduction of angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists. High potassium concentrations in heart failure could lead to life threatening events, and therefore should be taken seriously. In this review we summarise the information about potassium homeostasis in heart failure and the current risk of developing potentially serious hyperkalaemia, particularly in association with the use of aldosterone antagonists.
No takes yet. Share an insight, caveat, or question.
Poggio et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: